What is the drug abiraterone used for?
Abiraterone is used in combination with prednisone to treat a certain type of prostate cancer that has spread to other parts of the body. Abiraterone is in a class of medications called androgen biosynthesis inhibitors. It works by decreasing the amount of certain hormones in the body.
What was the median overall survival in the abiraterone placebo group in AA 302 trial?
Median overall survival was significantly longer in the abiraterone acetate group than in the placebo group (34.7 months [95% CI 32.7-36.8] vs 30.3 months [28.7-33.3]; hazard ratio 0.81 [95% CI 0.70-0.93]; p=0.0033).
What are the side effects of abiraterone?
Side Effects
- Bladder pain.
- bloating or swelling of the face, arms, hands, lower legs, or feet.
- bloody or cloudy urine.
- bone pain or fracture.
- chest pain or discomfort.
- decreased urine.
- difficult, burning, or painful urination.
- fast, pounding, or irregular heartbeat or pulse.
How good is abiraterone?
Expert opinion: Abiraterone is highly effective and has an excellent safety profile for the treatment of metastatic castrate-naïve prostate cancer. It is the authors’ opinion that it should now be considered the new standard of care.
What company makes xtandi?
XTANDI® (enzalutamide) Approved by U.S. FDA for the Treatment of Metastatic Castration-Sensitive Prostate Cancer | Pfizer.
What happens when abiraterone stops working?
If these stop working, the drugs abiraterone (Zytiga), apaleutamide (Erleada), darolutamide (Nubeqa), or enzalutamide (Xtandi) may be effective. The most frequent side effects from hormone therapy include reduced sex drive, impotence, erectile dysfunction, infertility, and bone loss.
Who makes abiraterone?
ZYTIGA (abiraterone acetate) was developed by Ortho Biotech Oncology Research & Development, a Unit of Cougar Biotechnology, Inc., and will be marketed by Centocor Ortho Biotech Inc.
What’s new in the cou-aa-302 study?
Additional investigators in the COU-AA- 302 study are listed in the Supplementary Appendix, available at NEJM.org. Abiraterone acetate, an androgen biosynthesis inhibitor, improves overall survival in patients with metastatic castration-resistant prostate cancer after chemotherapy.
What is abiraterone acetate plus prednisone used for?
Abiraterone in metastatic prostate cancer without previous chemotherapy. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial.
How many mCRPC patients are treated with AAP in cou-aa-302?
Design, setting, and participants: A total of 1088 mCRPC patients treated with either AAP or prednisone in the first-line setting in COU-AA-302 were included in this post hoc analysis. Intervention: Abiraterone acetate1000mg daily versus placebo, both plus prednisone 10mg daily.
Is abiraterone acetate effective in patients who have never had chemotherapy?
We evaluated this agent in patients who had not received previous chemotherapy. In this double-blind study, we randomly assigned 1088 patients to receive abiraterone acetate (1000 mg) plus prednisone (5 mg twice daily) or placebo plus prednisone. The coprimary end points were radiographic progression-free survival and overall survival.
